Clinical tools for chemotherapy toxicity prediction and survival in geriatric cancer patients

References

• Muller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.
   PubMed Web of Science ®Google Scholar
• Falandry C, Brain E, Bonnefoy M, Mefti F, Jovenin N, Rigal O, et al. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients; Final results of the DOGMES multicenter GINECO trial. Eur J Cancer. 2013;49(13):2806–14.
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen ML, Maas HA, Koning CC, van der Bruggen-Bogaarts BA, Groen HJ, Wymenga AN. Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer. J Geriatr Oncol. 2014;5(1):71–7.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer. 2007;43(10):1514–28.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Seynaeve C, Wymenga AN, van Tinteren H, Nortier JW, Maartense E, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch Breast Cancer Trialists’ Group. Breast. 2014;23(1):81–7.
   PubMed Web of Science ®Google Scholar
• Gironés R, Torregrosa D, Maestu I, Gómez-Codina J, Tenias JM, Rosell Costa R. Comprehensive Geriatric Assessment (CGA) of elderly lung cancer patients: A single-center experience. J Geriatr Oncol. 2012;3:98–103
   Web of Science ®Google Scholar
• Korc-Grodzicki B, Holmes HM, Shahrokni A. Geriatric assessment for oncologists. Cancer Biol Med. 2015;12:261–74
   PubMed Web of Science ®Google Scholar
• Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112(9):1435–44.
   PubMed Web of Science ®Google Scholar
• Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000;35(3):147–54.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, Maartense E, le Cessie S, Giltay EJ, Verlaan HA, van der Geest LG, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol. 2011;79(2):205–12.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, Maartense E, Nortier HJ, van der Geest LG, le Cessie S, Tanis BC, et al. Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly. Acta Oncol. 2016;55(1):15–23.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, Blanc J-F, Ceccaldi J, Mertens C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829–34.
   PubMed Web of Science ®Google Scholar
• Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17:838–46
   PubMed Web of Science ®Google Scholar
• Olivieri A, Gini G, Bocci C, Montanari M, Trappolini S, Olivieri J, et al. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist. 2012;17:663–72
   PubMed Web of Science ®Google Scholar
• Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011;22:1520–7
   PubMed Web of Science ®Google Scholar
• Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014;32:19–26
   PubMed Web of Science ®Google Scholar
• Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72
   PubMed Web of Science ®Google Scholar
• Ferrat E, Paillaud E, Caillet P, Laurent M, Tournigand C, Lagrange J-L, et al. Performance of four frailty classifications in older patients with cancer: Prospective elderly cancer patients cohort study. J Clin Oncol. 2017;35:1–12.
   PubMedGoogle Scholar
• Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106:462–69
   PubMed Web of Science ®Google Scholar
• Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15:e404–e14
   PubMed Web of Science ®Google Scholar
• Ferrat E, Audureau E, Paillaud E, Liu E, Tournigand C, Lagrange J-L, et al. Four distinct health profiles in older patients with cancer: latent class analysis of the prospective ELCAPA cohort. J Gerontol A Biol Sci Med Sci. 2016;71:1653–60
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Vos AG, Smorenburg CH, De Rooij SE, van Munster BC. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist. 2012;17:1439–49
   PubMed Web of Science ®Google Scholar
• Sattar S, Alibhai SM, Wildiers H, Puts MT. How to implement a geriatric assessment in your clinical practice. Oncologist. 2014;19:1056–68
   PubMed Web of Science ®Google Scholar
• Puts MT, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol. 2014;25:307–15
   PubMed Web of Science ®Google Scholar
• Versteeg KS, Konings IR, Lagaay AM, van de Loosdrecht AA, Verheul HM. Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. Ann Oncol. 2014;25:1914–8
   PubMed Web of Science ®Google Scholar
• Marinello R, Marenco D, Roglia D, Stasi MF, Ferrando A, Ceccarelli M, et al. Predictors of treatment failures during chemotherapy: a prospective study of 110 older cancer patients. Arch Gerontol Geriatr. 2009;48:222–6
   PubMed Web of Science ®Google Scholar
• Shin D-Y, Lee J-O, Kim YJ, Park M-S, Lee K-W, Kim K-I, et al. Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: a prospective cohort study using Comprehensive Geriatric Assessment. J Geriatr Oncol. 2012;3:359–67
   Web of Science ®Google Scholar
• Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S, et al. Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol. 2011;78:138–49
   PubMed Web of Science ®Google Scholar
• Massa E, Madeddu C, Astara G, Pisano M, Spiga C, Tanca FM, et al. An attempt to correlate a “Multidimensional Geriatric Assessment” (MGA), treatment assignment and clinical outcome in elderly cancer patients: Results of a phase II open study. Crit Rev Oncol Hematol. 2008;66:75–83
   PubMed Web of Science ®Google Scholar
• Basso U, Tonti S, Bassi C, Brunello A, Pasetto LM, Scaglione D, et al. Management of frail and not-frail elderly cancer patients in a hospital-based geriatric oncology program. Crit Rev Oncol Hematol. 2008;66:163–70
   PubMed Web of Science ®Google Scholar
• Voorrips LE, Ravelli AC, Dongelmans PC, Deurenberg P, Van Staveren WA. A physical activity questionnaire for the elderly. Med Sci Sports Exerc. 1991;23:974–9
   PubMed Web of Science ®Google Scholar
• Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, et al. Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer. 2003;11:460–4
   PubMed Web of Science ®Google Scholar
• Freyer G, Geay J-F, Touzet S, Provencal J, Weber B, Jacquin J-P, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795–800
   PubMed Web of Science ®Google Scholar
• Aparicio T, Jouve J-L, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31:1464–70
   PubMed Web of Science ®Google Scholar
• Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, et al. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer. 2017;74:98–108
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy Risk Assessment Scale for High-Age patients (CRASH) score. Cancer. 2012;118:3377–86
   PubMed Web of Science ®Google Scholar
• Extermann M, Bonetti M, Sledge GW, O’Dwyer PJ, Bonomi P, Benson III AB. MAX2-a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004;40:1193–8
   PubMed Web of Science ®Google Scholar
• Huria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol. 2011;29:3457–65
   PubMed Web of Science ®Google Scholar
• Huria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34:2366–71
   PubMed Web of Science ®Google Scholar
• Alibhai SM, Aziz S, Manokumar T, Timilshina N, Breunis H. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer. J Geriatr Oncol. 2017;8:31–6
   PubMed Web of Science ®Google Scholar
• Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton Frail Scale. Age Ageing. 2006;35:526–9
   PubMed Web of Science ®Google Scholar
• Keenan LG, O’Brien M, Ryan T, Dunne M, McArdle O. Assessment of older patients with cancer: Edmonton Frail Scale (EFS) as a predictor of adverse outcomes in older patients undergoing radiotherapy. J Geriatr Oncol. 2017;8(3):206–10.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-Fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264–8
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6
   PubMed Web of Science ®Google Scholar